PL2056863T3 - Leczenie chorób oczu - Google Patents

Leczenie chorób oczu

Info

Publication number
PL2056863T3
PL2056863T3 PL07784622T PL07784622T PL2056863T3 PL 2056863 T3 PL2056863 T3 PL 2056863T3 PL 07784622 T PL07784622 T PL 07784622T PL 07784622 T PL07784622 T PL 07784622T PL 2056863 T3 PL2056863 T3 PL 2056863T3
Authority
PL
Poland
Prior art keywords
treatment
ocular diseases
ocular
diseases
Prior art date
Application number
PL07784622T
Other languages
English (en)
Inventor
Ahmed Aftab
Lucia Desser
Bernhard Lotz
Thomas Mohr
Original Assignee
Marlyn Nutraceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marlyn Nutraceuticals, Inc. filed Critical Marlyn Nutraceuticals, Inc.
Publication of PL2056863T3 publication Critical patent/PL2056863T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07784622T 2006-08-16 2007-08-16 Leczenie chorób oczu PL2056863T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0137606A AT504159A1 (de) 2006-08-16 2006-08-16 Verwendung von proteasen
EP07784622.8A EP2056863B1 (en) 2006-08-16 2007-08-16 Treatment of ocular diseases

Publications (1)

Publication Number Publication Date
PL2056863T3 true PL2056863T3 (pl) 2017-11-30

Family

ID=38677891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07784622T PL2056863T3 (pl) 2006-08-16 2007-08-16 Leczenie chorób oczu

Country Status (15)

Country Link
US (1) US9795656B2 (pl)
EP (1) EP2056863B1 (pl)
JP (1) JP2010500382A (pl)
CN (1) CN101505790A (pl)
AT (1) AT504159A1 (pl)
CA (1) CA2658564A1 (pl)
DK (1) DK2056863T3 (pl)
ES (1) ES2628813T3 (pl)
HU (1) HUE034862T2 (pl)
MX (1) MX2009001745A (pl)
PL (1) PL2056863T3 (pl)
PT (1) PT2056863T (pl)
RU (1) RU2472523C2 (pl)
SI (1) SI2056863T1 (pl)
WO (1) WO2008019417A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009290466B2 (en) * 2008-09-10 2014-06-12 Pt. Dexa Medica Composition of thrombolytic agent and anti thrombosis and also its production method
EP2504025A4 (en) * 2009-11-23 2013-05-01 Stephen F Olmstead COMPOSITIONS AND METHODS USING SERRATIA PEPTIDASE FOR INHIBITING AND TREATING BIOFILMS ASSOCIATED WITH PARTICULAR SUFFERING
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
US20140154235A1 (en) 2011-05-12 2014-06-05 Smith & Nephew Orthopaedics Ag Wound debridement compositions containing seaprose and methods of wound treatment using same
AU2013259360B2 (en) 2012-05-11 2017-07-13 Smith & Nephew, Inc. Use of Seaprose to remove bacterial biofilm
ITMI20121997A1 (it) * 2012-11-23 2014-05-24 Velleja Res Srl Composizioni fibrinolitiche per la prevenzione e il trattamento degli stati flebotrombotici
ITMI20130117A1 (it) * 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
US20140212405A1 (en) * 2013-01-28 2014-07-31 2294719 Ontario Limited Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions
US11065310B2 (en) 2016-05-27 2021-07-20 Nattocat, LLC Compositions and methods for thromboembolism dissolution
US11628207B2 (en) 2016-07-27 2023-04-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
JP7429503B2 (ja) * 2019-06-24 2024-02-08 小林製薬株式会社 ナットウキナーゼを含む経口組成物
TW202202168A (zh) * 2020-07-07 2022-01-16 洪啟庭 用於改善玻璃體混濁的組成物及其應用
CN113769073A (zh) * 2021-10-15 2021-12-10 杭州鑫伟低碳技术研发有限公司 一种利用生物酶治疗眼底出血的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030612A (en) * 1994-11-22 2000-02-29 Phairson Medical Inc. Antimicrobial uses of multifunctional enzyme
AU730211B2 (en) * 1996-11-19 2001-03-01 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
DE19726251C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme zur Behandlung von Uveitis
CA2327541A1 (en) * 1998-05-22 1999-12-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US20040086537A1 (en) * 1998-08-20 2004-05-06 Jun Inoue Prophylactic or threapeutic composition for ocular circulation disorders
US20030027998A1 (en) 1998-10-30 2003-02-06 Holtzman Douglas A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US7559718B2 (en) * 1999-01-27 2009-07-14 Trimble Navigation Limited Transducer arrangement
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
EP1539222A1 (en) * 2002-07-02 2005-06-15 The Regents Of The University Of California Treatment for eye disorder
AU2004249904A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7354569B2 (en) * 2003-07-11 2008-04-08 Colgate-Palmolive Company Chewable antiplaque confectionery dental composition
WO2005056784A1 (ja) * 2003-12-15 2005-06-23 Japan Science And Technology Agency インスリン誘導性ポリペプチド
DK1735439T3 (da) * 2004-04-12 2012-02-06 Catalyst Biosciences Inc Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
WO2005100556A2 (en) 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
US20060083727A1 (en) * 2004-07-15 2006-04-20 Nanobac Pharmaceuticals, Inc. Methods and compositions for the treatment of diseases characterized by calcification and/or plaque formation
JPWO2006025276A1 (ja) * 2004-08-31 2008-05-08 国立大学法人 熊本大学 ナットウキナーゼを含む眼科疾患の治療・予防剤
EP2012826B1 (en) * 2006-05-04 2016-04-13 Fovea Pharmaceuticals Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases

Also Published As

Publication number Publication date
MX2009001745A (es) 2009-07-10
ES2628813T3 (es) 2017-08-04
US20110311509A1 (en) 2011-12-22
PT2056863T (pt) 2017-07-04
US9795656B2 (en) 2017-10-24
WO2008019417A2 (en) 2008-02-21
SI2056863T1 (sl) 2017-10-30
RU2009109358A (ru) 2010-09-27
JP2010500382A (ja) 2010-01-07
EP2056863B1 (en) 2017-03-22
WO2008019417A3 (en) 2008-05-29
DK2056863T3 (en) 2017-07-10
CN101505790A (zh) 2009-08-12
RU2472523C2 (ru) 2013-01-20
EP2056863A2 (en) 2009-05-13
HUE034862T2 (en) 2018-03-28
AT504159A1 (de) 2008-03-15
CA2658564A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
SI2056863T1 (sl) Zdravljenje očesnih bolezni
EP2187743A4 (en) FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
IL200528A0 (en) Methods of treating ophthalmic diseases
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
PL2056807T3 (pl) Leczenie chorób zakaźnych
IL190779A0 (en) Compositions for treatment of eye diseases
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
IL197118A0 (en) Ultrasonic treatment of glaucoma
ZA200903862B (en) Nutritional supplement composition for treatment of ocular diseases
ZA200806808B (en) Treatment of stressed patients
EP2148667A4 (en) USE OF CYCLOHEXANHEXOL DERIVATIVES IN THE TREATMENT OF EYE DISEASES
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0523961D0 (en) The treatment of ophthalmic diseases
GB0428218D0 (en) Medicament for Treatment of Inflammatory Diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
GB0623740D0 (en) Treatment of disease
ZA200904660B (en) Treatment of IL-1-Beta related diseases
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
ZA200906883B (en) Methods of treating ophthalmic diseases